Scientists attack tough esophageal cancer with powerful drug trio before surgery
NCT ID NCT04229459
Summary
This study is testing whether adding two immunotherapy drugs (nivolumab and cetuximab) to standard chemotherapy and radiation before surgery helps people with a specific type of advanced esophageal cancer. The goal is to see if this combination can shrink or eliminate the tumor more effectively before it is surgically removed. The trial is for adults with newly diagnosed cancer who have not had any prior treatment for it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rabin Medical Center
Petah Tikva, Israel
Conditions
Explore the condition pages connected to this study.